sb 203580 has been researched along with globotriaosylceramide in 2 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (globotriaosylceramide) | Trials (globotriaosylceramide) | Recent Studies (post-2010) (globotriaosylceramide) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 732 | 32 | 245 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hughes, AK; Kohan, DE; Stricklett, PK | 1 |
| Kolling, GL; Lindner, MH; Obrig, TG; Stone, MK | 1 |
2 other study(ies) available for sb 203580 and globotriaosylceramide
| Article | Year |
|---|---|
Inhibition of p38 mitogen-activated protein kinase ameliorates cytokine up-regulated shigatoxin-1 toxicity in human brain microvascular endothelial cells.
Topics: Brain; Cells, Cultured; Endothelial Cells; Enzyme Inhibitors; Galactosyltransferases; Glucosyltransferases; Humans; Imidazoles; Microcirculation; p38 Mitogen-Activated Protein Kinases; Pyridines; Shiga Toxin 1; Signal Transduction; Trihexosylceramides; Tumor Necrosis Factor-alpha; Up-Regulation | 2005 |
p38 mitogen-activated protein kinase mediates lipopolysaccharide and tumor necrosis factor alpha induction of shiga toxin 2 sensitivity in human umbilical vein endothelial cells.
Topics: Cell Survival; Cells, Cultured; Cycloheximide; Dose-Response Relationship, Drug; Endothelial Cells; Enzyme Inhibitors; Escherichia coli O157; Gene Silencing; Humans; Imidazoles; Lipopolysaccharides; p38 Mitogen-Activated Protein Kinases; Pyridines; Shiga Toxin 2; Time Factors; Trihexosylceramides; Tumor Necrosis Factor-alpha | 2008 |